NVAX

Novavax, Inc. (NVAX) Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Novavax, Inc. is a biotechnology company focused on vaccine development, utilizing its recombinant protein-based nanoparticle technology and Matrix-M® adjuvant. The company's strategic priorities include its partnership with Sanofi Pasteur, leveraging its technology platform for new partnerships, and advancing its early-stage pipeline. The company operates as a single reporting segment.

Key Financial Metrics

Note: Working capital calculated as Total Current Assets ($868,028) minus Total Current Liabilities ($422,170).

Material Changes vs. Prior Period

• Revenue Surge: Total revenue increased by $572.8 million (610%) compared to Q1 2024. This was primarily driven by the recognition of $575.7 million in product sales resulting from the termination of the Advance Purchase Agreement (APA) with the Canadian government and $27.3 million from the settlement of the New Zealand APA.
• Profitability Turnaround: The company reported a net income of $518.6 million, a swing of $666.2 million from the net loss of $147.6 million in Q1 2024. This was driven by the revenue recognition described above and a significant reduction in operating expenses.
• Expense Reduction: Total expenses decreased by $87.5 million to $151.1 million. Selling, general, and administrative (SG&A) expenses dropped $38.7 million, and Cost of Sales decreased $45.1 million, largely due to reduced inventory write-downs and lower unutilized manufacturing capacity charges.
• Sanofi Partnership Revenue: Licensing, royalties, and other revenue increased to $45.0 million, primarily due to $40.3 million recognized from transition services and technology transfer under the Sanofi Collaboration and License Agreement (CLA).

Guidance, Outlook, Risks, and Unusual Items

• Regulatory Status (COVID-19): The Biologics License Application (BLA) for the company's COVID-19 vaccine is under review by the U.S. FDA. In April 2025, the FDA issued an information request for a Post Marketing Commitment (PMC) to generate additional clinical data. Management believes the BLA is approvable upon alignment on the PMC details.
• Sanofi Milestones: Achievement of BLA approval triggers a $175 million milestone payment from Sanofi. Additional milestones totaling up to $650 million remain outstanding, contingent on regulatory approvals, technology transfer, and sales performance.
• Takeda Agreement: In April 2025, Novavax amended its agreement with Takeda for the Japanese market, securing a $20 million upfront payment and improved royalty terms.
• Liquidity and Going Concern: As of March 31, 2025, the company held $731.4 million in cash, cash equivalents, and marketable securities. Management concluded it has sufficient capital to fund operations for at least one year from the filing date.
• Legal Settlements: The company recorded a net gain of $4.8 million in Q1 2025 related to the settlement of derivative litigation, where individual defendants paid $6.8 million to Novavax.
• Risks: Key risks include the potential failure to meet regulatory milestones for the Australia APA (which could result in refunds of up to $92.5 million), delays in FDA approval, and the company's dependence on third-party manufacturers (Serum Institute of India) for supply.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of revenue streams, as Q1 2025 results were heavily influenced by one-time revenue recognition from terminated APAs (Canada and New Zealand) rather than recurring product sales.
• FDA PMC Resolution: Monitor the status of the FDA's Post Marketing Commitment request and the timeline for the proposed study design, as this directly impacts the $175 million Sanofi milestone and future commercialization.
• Australia APA Obligations: Assess the risk of refunding up to $92.5 million of deferred revenue if the updated COVID-19 vaccine is not approved and delivered by December 31, 2025.
• Cash Burn Rate: Review the net cash used in operating activities ($185.5 million) against current cash reserves to evaluate runway without additional financing or milestone payments.
• Sanofi Collaboration Execution: Track progress on technology transfer and regulatory approvals required to unlock the remaining $650 million in potential Sanofi milestones.